European Drug Regulator Slaps Safety Warning On J&J Jab Due To Blood-Clot Links

While Europe grapples with its own vaccine safety scandal, the EMA, the same EU pharma regulator that has insisted that the AstraZeneca-Oxford jab's benefits far outweigh its risk, has just poured cold water on J&J's vaccine.

Although the EMA said the reported combination of blood clots and low blood platelets is very rare, and the overall benefits of J&J's COVID-19 Vaccine Janssen in preventing COVID-19 outweigh the risks of side effects, the EMA has decided to affix a safety warning to the J&J jab - a warning that EMA neglected to impose on the AstraZeneca jab that is so critical to the Continent's vaccination program.

The EMA's safety committee, known as PRAC, determined that blood clots caused by the vaccine occurred mostly at unusual sites such as in veins in the brain (cerebral venous sinus thrombosis, CVST) and the abdomen (splanchnic vein thrombosis) as well as in the arteries. They're often accompanied with low levels of blood platelets and sometimes bleeding. The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria, the committee said.

1 2
View single page >> |

Disclaimer: Copyright ©2009-2021 ZeroHedge.com/ABC Media, LTD; All Rights Reserved. Zero Hedge is intended for Mature Audiences. Familiarize yourself with our legal and use policies every time ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.